Nyxoah (NASDAQ:NYXH) Price Target Cut to $13.00 by Analysts at Oppenheimer

Nyxoah (NASDAQ:NYXH) had its target price reduced by Oppenheimer from $15.00 to $13.00 in a research report released on Wednesday morning, Benzinga reports. They currently have an outperform rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reduced their target price on shares of Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a research report on Wednesday, May 15th. Stifel Nicolaus reduced their target price on shares of Nyxoah from $27.00 to $19.00 and set a buy rating for the company in a research report on Monday, June 24th. Finally, HC Wainwright reaffirmed a buy rating and set a $18.00 price objective on shares of Nyxoah in a research report on Wednesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and an average price target of $17.20.

Nyxoah Stock Performance

Shares of Nyxoah stock traded up $0.20 during trading on Wednesday, reaching $8.54. The company’s stock had a trading volume of 5,170 shares, compared to its average volume of 44,131. The business’s 50-day moving average price is $8.34 and its 200-day moving average price is $10.62. The firm has a market cap of $212.99 million, a PE ratio of -5.21 and a beta of 1.44. Nyxoah has a 52 week low of $4.00 and a 52 week high of $20.00. The company has a quick ratio of 3.70, a current ratio of 3.94 and a debt-to-equity ratio of 0.13.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Tuesday, May 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.45). The company had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.20 million. Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. Equities analysts forecast that Nyxoah will post -1.72 earnings per share for the current year.

Institutional Investors Weigh In On Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. Iron Triangle Partners LP bought a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 253,025 shares of the company’s stock, valued at approximately $3,413,000. Nyxoah makes up about 0.3% of Iron Triangle Partners LP’s portfolio, making the stock its 28th biggest position.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.